Galderma Patient Services for Nemluvio

Offering a path for every patient

Your real-time navigation partner to help patients start and stay on NEMLUVIO

GPS (Galderma Patient Services) for NEMLUVIO™ is a free program that offers a path for every patient to treatment with access to different patient services, including a suite of patient support and financial assistance programs.1

Go To Enrollment Form 

85%

commercial coverage at parity to dupilumab; first-line preferred brand without a biologic step

Get NEMLUVIO fast

  1. Fully complete the NEMLUVIO® Enrollment Form with patient consent

      Enrollment Form

  2. Send form to in‑network Specialty Pharmacy of choice

      Specialty Pharmacy List 

  3. Specialty Pharmacy will confirm insurance coverage and coordinate program eligibility, so your patient receives NEMLUVIO right to their door*

Start therapy

Quick Start Program

Treatment-naïve patients will receive their first/loading dose while awaiting prior authorization (PA) decision. Available to eligible commercially insured patients. Patients can receive 2 additional refills.

Note: If there are further delays in the PA approval process, patients may move to Bridge Program. Please be sure to fill out the Free Goods prescription on the Enrollment Form to make sure your patients can get started quickly.

Patient Assistance Program

Eligible patients with no insurance or inadequate coverage can receive NEMLUVIO at no cost.

Co-Pay Assistance

With Co-Pay Assistance, qualified patients with a prescription may pay as little as $0.

Stay on track

Nurse Educator Support

NEMLUVIO Nurse Educators are available virtually or over the phone to provide injection training and ongoing disease management support to your patients.​

Note: You may request injection training and view the injection training video at https://galdermaps.iassist.com/​.

Bridge Program

Helps eligible patients stay on NEMLUVIO during changes in ​insurance coverage or if there is a delay in coverage determination.

Injection Training

Educates patients on recommended preparation and administration techniques. May be done virtually or telephonically.

With Co-Pay Assistance, eligible patients may pay as little as $0

The Co-Pay program helps commercially insured patients reduce or eliminate out-of-pocket costs and improve affordability.

  • Qualified, commercially insured patients may pay as little as $0 for their treatment
  • Patients will be automatically re-enrolled for the following year if they are still on the same treatment
ENROLL YOUR PATIENTS 

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

  • the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
  • the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

  • Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia. 
  • Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular. 

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug-associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.